HIF1A and B-cell chronic lymphocytic leukemia: In leukaemia settings, by adjusting EZN-2208 dosage to non-cytotoxic concentrations, we have demonstrated that this compound can impair myeloid leukaemia and CLL progression in vivo via HIF-1α inhibition [4,6].